Table 1 Single knockouts of the therapeutic targets from the TTD database that perturb the RA macrophages’ phenotypes.
From: Large-scale computational modelling of the M1 and M2 synovial macrophages in rheumatoid arthritis
Target | Target type | Associated disease(s) | Drugs with the highest status | Effect on the RA macrophages’ phenotypes |
|---|---|---|---|---|
NFkB | Successful | Irritable bowel syndrome, Rheumatoid arthritis, Choreiform disorder, Lupus erythematosus, Multiple sclerosis,… | Sulfasalazine (Approved) | -Induction of the M1 macrophage apoptosis -Suppression of the M1 macrophage proliferation |
ERK1 | Clinical trial target | Melanoma, Pancreatic cancer, Cancer, Arteries/arterioles disorder, Mature T-cell lymphoma. | BVD-523 (Phase 2) | Suppression of the M1 macrophage proliferation |
GSK3B | Clinical trial target | Myotonic disorder, Acute myeloid leukaemia, Osteosarcoma, Fragile X chromosome, Myeloproliferative neoplasm,… | Tideglusib (Phase 2/3) | -Induction of the M2 macrophage proliferation -Suppression of the M2 macrophage apoptosis |
